Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241344 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01241344 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT01241344, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study was designed to assess the safety and efficacy of preemptive treatment with oral brincidofovir (BCV), as compared to placebo, for the prevention of adenovirus (AdV) disease in recipients of hematopoietic stem cell transplantation (HCT) with asymptomatic AdV viremia.
Interventions
- OTHER Placebo
- DRUG Brincidofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01241344
The ClinicalTrials.gov registry entry for NCT01241344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01241344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01241344 about?
NCT01241344 is a clinical study titled "Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease". This study was designed to assess the safety and efficacy of preemptive treatment with oral brincidofovir (BCV), as compared to placebo, for the prevention of adenovirus (AdV) disease in recipients of hematopoietic stem cell transplantation (HCT) with asymptomatic AdV viremia.
What is the current status of trial NCT01241344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01241344?
The interventions under investigation include: Placebo (OTHER), Brincidofovir (DRUG).
Who is sponsoring clinical trial NCT01241344?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.